10X Genomics (TXG) stock
Last close $51.80 on 2026-11-20 (-9.72%) · Sector: Healthcare
10X Genomics develops tools that help scientists study biology one cell at a time, which can reveal how diseases start and how the body works. It makes money by selling instruments, the chemical kits and supplies used in each experiment, and related software to universities, hospitals and drug companies.
The business is shrinking a little, with revenue down 3.1% over the past year, and it still loses money on most quarters. The stock has been far more volatile than the market, but over the past year it rose 214.7% while the S&P 500 rose 5.7%, so it beat the market. The share price is now 49.6% below its 52-week high, and insiders sold about $12.6 million of stock in the last 90 days with no insider buys.
Key numbers
- Market cap: $6.8B
- Revenue (last 12 months): $0.62B
- Revenue growth: -3.1%
- Gross margin: 72.0%
- Operating margin: -12.9%
- P/S: 10.9
- Debt to equity: 0.00
- Current ratio: 5.14
Quality score
Overall 42/100 · growth 28 · profitability 5 · financial health 92 · value None
Performance and risk
1-year return +214.7% vs S&P 500 +5.7% · volatility 76.9% (S&P 500 14.3%) · largest drop -47.0% · beta 2.50
Stock move the day after earnings
- 2026-01-12: +3.6%
- 2026-02-12: +3.5%
- 2026-05-07: -3.7%
- 2026-08-06: +14.1%
- 2026-11-05: +2.1%
Insider trades (12 months)
Bought $0.0M · sold $18.7M
TXG stock research · TXG options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.